(Q24186168)

2

0 references

Salima Punja

1

0 references

Jane Nikles Nikles

6

object named as

Jane Nikles

0 references

Lisa Hartling

3

object named as

Lisa Hartling

0 references

author name string

Liana Urichuk

4

0 references

Ben Vandermeer

Cochrane Database of Systematic Reviews

5

0 references

publication date

4 February 2016

0 references

published in

0 references

cites work

A randomized, double-blind, placebo-controlled, parallel-group study of SLI381 (Adderall XR) in children with attention-deficit/hyperactivity disorder

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009996.PUB2

Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/hyperactivity disorder: a phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009996.PUB2

Motor/vocal tics and compulsive behaviors on stimulant drugs: is there a common vulnerability?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009996.PUB2

Stimulant drug treatment of hyperactivity: biochemical correlates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009996.PUB2

Methylphenidate and dextroamphetamine treatments of hyperactivity: are there true nonresponders?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009996.PUB2

Classroom academic performance: improvement with both methylphenidate and dextroamphetamine in ADHD boys.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009996.PUB2

The Efficacy and Safety of Evekeo, Racemic Amphetamine Sulfate, for Treatment of Attention-Deficit/Hyperactivity Disorder Symptoms: A Multicenter, Dose-Optimized, Double-Blind, Randomized, Placebo-Controlled Crossover Laboratory Classroom Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009996.PUB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009996.PUB2

European, randomized, phase 3 study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009996.PUB2

Efficacy of lisdexamfetamine dimesylate throughout the day in children and adolescents with attention-deficit/hyperactivity disorder: results from a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009996.PUB2

Fenfluramine and dextroamphetamine treatment of childhood hyperactivity. Clinical and biochemical findings.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009996.PUB2

Efficacy and safety of lisdexamfetamine dimesylate in adolescents with attention-deficit/hyperactivity disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009996.PUB2

Effect of lisdexamfetamine dimesylate on sleep in children with ADHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009996.PUB2

Long-term stimulant treatment of children with attention-deficit hyperactivity disorder symptoms. A randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009996.PUB2

Double-blind, placebo-controlled study of single-dose amphetamine formulations in ADHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009996.PUB2

Analog classroom assessment of a once-daily mixed amphetamine formulation, SLI381 (Adderall XR), in children with ADHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009996.PUB2

A double-blind, placebo-controlled study of Adderall and methylphenidate in the treatment of attention-deficit/hyperactivity disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009996.PUB2

Minimizing adverse events while maintaining clinical improvement in a pediatric attention-deficit/hyperactivity disorder crossover trial with dextroamphetamine and methylphenidate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009996.PUB2

Clinical gains from including both dextroamphetamine and methylphenidate in stimulant trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009996.PUB2

ADHD in girls: clinical comparability of a research sample.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009996.PUB2

Platelet MAO and measures of attention and impulsivity in boys with attention deficit disorder and hyperactivity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009996.PUB2

A prospective study of stimulant response in preschool children: insights from ROC analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009996.PUB2

Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009996.PUB2

Randomized trial of a home-based family intervention for children who have deliberately poisoned themselves

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009996.PUB2

A 13-hour laboratory school study of lisdexamfetamine dimesylate in school-aged children with attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009996.PUB2

Selegiline in the treatment of attention deficit hyperactivity disorder in children: a double blind and randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009996.PUB2

Zinc for attention-deficit/hyperactivity disorder: placebo-controlled double-blind pilot trial alone and combined with amphetamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009996.PUB2

A post hoc subgroup analysis of an 18-day randomized controlled trial comparing the tolerability and efficacy of mixed amphetamine salts extended release and atomoxetine in school-age girls with attention-deficit/hyperactivity disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009996.PUB2

Pharmacokinetics of lisdexamfetamine dimesylate and its active metabolite, d-amphetamine, with increasing oral doses of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: a single-dose, randomized, open-label, cro

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009996.PUB2

Improvements in executive function correlate with enhanced performance and functioning and health-related quality of life: evidence from 2 large, double-blind, randomized, placebo-controlled trials in ADHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009996.PUB2

Cardiovascular effects of mixed amphetamine salts extended release in the treatment of school-aged children with attention-deficit/hyperactivity disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009996.PUB2

Side effects of methylphenidate and dexamphetamine in children with attention deficit hyperactivity disorder: a double-blind, crossover trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009996.PUB2

Effectiveness, safety, and tolerability of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: an open-label, dose-optimization study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009996.PUB2

A Pharmacokinetic/Pharmacodynamic Study Comparing a Single Morning Dose of Adderall to Twice-Daily Dosing in Children With ADHD

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009996.PUB2

Effect of lisdexamfetamine dimesylate on parent-rated measures in children aged 6 to 12 years with attention-deficit/hyperactivity disorder: a secondary analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009996.PUB2

Long-term tolerability and effectiveness of once-daily mixed amphetamine salts (Adderall XR) in children with ADHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009996.PUB2

The efficacy and safety profile of lisdexamfetamine dimesylate, a prodrug of d-amphetamine, for the treatment of attention-deficit/hyperactivity disorder in children and adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009996.PUB2

An n-of-1 trial service in clinical practice: testing the effectiveness of stimulants for attention-deficit/hyperactivity disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009996.PUB2

Randomized, placebo-controlled trial of mixed amphetamine salts for symptoms of comorbid ADHD in pediatric bipolar disorder after mood stabilization with divalproex sodium.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009996.PUB2

Efficacy and safety of mixed amphetamine salts extended release (adderall XR) in the management of oppositional defiant disorder with or without comorbid attention-deficit/hyperactivity disorder in school-aged children and adolescents: A 4-week, mul

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009996.PUB2

Executive function deficits in children with attention-deficit/hyperactivity disorder and improvement with lisdexamfetamine dimesylate in an open-label study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009996.PUB2

Efficacy and tolerability of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: sex and age effects and effect size across the day.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009996.PUB2

Randomized, double-blind, placebo-controlled, crossover study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: novel findings using a simulated adult workplace environment design

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009996.PUB2

Impairment of social and moral behavior related to early damage in human prefrontal cortex

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009996.PUB2

Stimulants: Therapeutic actions in ADHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009996.PUB2

Patterns of psychiatric comorbidity, cognition, and psychosocial functioning in adults with attention deficit hyperactivity disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009996.PUB2

Amphetamines for Attention Deficit Hyperactivity Disorder (ADHD) in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009996.PUB2

Validity of the NIMH Diagnostic Interview Schedule for Children: a comparison between psychiatric and pediatric referrals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009996.PUB2

Language bias in randomised controlled trials published in English and German.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009996.PUB2

Grading quality of evidence and strength of recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009996.PUB2

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009996.PUB2

Industry sponsorship and research outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009996.PUB2

The worldwide prevalence of ADHD: a systematic review and metaregression analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009996.PUB2

CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009996.PUB2

Etiologic subtypes of attention-deficit/hyperactivity disorder: brain imaging, molecular genetic and environmental factors and the dopamine hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009996.PUB2

The pediatric cancer quality of life inventory-32 (PCQL-32): I. Reliability and validity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009996.PUB2

The COMET (Core Outcome Measures in Effectiveness Trials) Initiative: Its Role in Improving Cochrane Reviews

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009996.PUB2

Amphetamines for attention deficit hyperactivity disorder (ADHD) in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009996.PUB2

Why the Cochrane Risk of Bias Tool Should Include Funding Source as a Standard Item

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009996.PUB2

7 January 2021

Why the Cochrane Risk of Bias Tool Should not Include Funding Source as a Standard Item

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009996.PUB2

7 January 2021

Variance imputation for overviews of clinical trials with continuous response

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009996.PUB2

7 January 2021

Lisdexamfetamine dimesylate and mixed amphetamine salts extended-release in children with ADHD: a double-blind, placebo-controlled, crossover analog classroom study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009996.PUB2

7 January 2021

Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009996.PUB2

7 January 2021

Amino acid supplementation as therapy for attention deficit disorder

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009996.PUB2

7 January 2021

The revised Conners' Parent Rating Scale (CPRS-R): factor structure, reliability, and criterion validity

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009996.PUB2

7 January 2021

Revision and restandardization of the Conners Teacher Rating Scale (CTRS-R): factor structure, reliability, and criterion validity

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009996.PUB2

7 January 2021

Differential effectiveness of methylphenidate and Adderall in school-age youths with attention-deficit/hyperactivity disorder

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009996.PUB2

7 January 2021

Effects of stimulant medication on neuropsychological functioning in young adults with attention-deficit/hyperactivity disorder.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009996.PUB2

7 January 2021